|
11 Dec 2019 |
AffaMed Therapeutics Receives NMPA Approval to Initiate Phase III Clinical Trial in China with Herceptin® (Trastuzumab) Biosimilar Candidate AMT901
|
|
11 Dec 2019 |
Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease
|
|
11 Dec 2019 |
Navigen Announces FDA Clearance of its IND Application to Initiate First-in-Human Studies for CPT31, a Novel, D-peptide HIV Entry Inhibitor
|
|
11 Dec 2019 |
Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections
|
|
11 Dec 2019 |
Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
|
|
11 Dec 2019 |
EicOsis Announces First Subject Dosed in Phase 1a Clinical Trial of EC5026
|
|
11 Dec 2019 |
Darzalex (daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma
|
|
11 Dec 2019 |
GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history
|
|
11 Dec 2019 |
LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD
|
|
11 Dec 2019 |
BioInvent and Transgene announce compelling preclinical data for BT-001 in solid tumors
|
|
11 Dec 2019 |
FDA Accepts Supplemental Biologics License Application for Xolair (Omalizumab) for the Treatment of Nasal Polyps
|
|
11 Dec 2019 |
First patient dosed in BIVV001 phase 3 XTEND-1 study in people with severe haemophilia A
|
|
10 Dec 2019 |
Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene
|
|
10 Dec 2019 |
Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001
|
|
10 Dec 2019 |
Daiichi Sankyo Initiates Pivotal Phase 2 Trial in Japan with Valemetostat in Patients with Adult T-Cell Leukemia-Lymphoma
|
|
10 Dec 2019 |
ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting
|
|
10 Dec 2019 |
Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic C
|
|
10 Dec 2019 |
Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
|
|
10 Dec 2019 |
Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation
|
|
10 Dec 2019 |
Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting
|
